[

umifenovir

]
The FAITH study enrolled a total of 158 hospitalised patients with moderate symptoms of Covid-19 in India.(REUTERS File)

Combination of antiviral drugs shows ‘no superior outcome’ for Covid treatment: Firm

Hindustan Times, New Delhi | By Rhythma Kaul
PUBLISHED ON OCT 10, 2020 10:04 AM IST
In May, Glenmark had received approval from DCGI to conduct phase 3 clinical trials in the country using a combination of antiviral drugs Favipiravir and Umifenovir as a potential Covid-19 treatment strategy
Finished tablets sit inside an unsealed container during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia.(Bloomberg)
Finished tablets sit inside an unsealed container during the manufacture of the Favipiravir antiviral medicine at a plant in Khimki, Russia.(Bloomberg)

Glenmark to study efficacy of two antiviral drugs for treating Covid-19

Hindustan Times, New Delhi | By Rhythma Kaul
UPDATED ON MAY 26, 2020 05:36 PM IST
Favipiravir is an oral antiviral drug approved in Japan since 2014 for treating novel or re-emerging influenza virus infections. Umifenovir is another oral antiviral drug licenced for the treatment and prophylaxis of influenza A and B infections in Russia and China.
SHARE
Story Saved